JP2006517973A - 新規な治療方法および局所投与用組成物 - Google Patents

新規な治療方法および局所投与用組成物 Download PDF

Info

Publication number
JP2006517973A
JP2006517973A JP2006503567A JP2006503567A JP2006517973A JP 2006517973 A JP2006517973 A JP 2006517973A JP 2006503567 A JP2006503567 A JP 2006503567A JP 2006503567 A JP2006503567 A JP 2006503567A JP 2006517973 A JP2006517973 A JP 2006517973A
Authority
JP
Japan
Prior art keywords
skin
nominal flux
photoaging
flux
drug substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006503567A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006517973A5 (enExample
Inventor
デイビス，エイドリアン，フランシス
トロテット，ライオネル
Original Assignee
スミスクライン ビーチャム コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スミスクライン ビーチャム コーポレーション filed Critical スミスクライン ビーチャム コーポレーション
Publication of JP2006517973A publication Critical patent/JP2006517973A/ja
Publication of JP2006517973A5 publication Critical patent/JP2006517973A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2006503567A 2003-02-17 2004-02-13 新規な治療方法および局所投与用組成物 Withdrawn JP2006517973A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0303609.2A GB0303609D0 (en) 2003-02-17 2003-02-17 Novel therapeutic method and compositions
PCT/US2004/004329 WO2004073622A2 (en) 2003-02-17 2004-02-13 Novel therapeutic method and compositions for topical administration

Publications (2)

Publication Number Publication Date
JP2006517973A true JP2006517973A (ja) 2006-08-03
JP2006517973A5 JP2006517973A5 (enExample) 2007-03-29

Family

ID=9953158

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006503567A Withdrawn JP2006517973A (ja) 2003-02-17 2004-02-13 新規な治療方法および局所投与用組成物

Country Status (4)

Country Link
EP (1) EP1594959A4 (enExample)
JP (1) JP2006517973A (enExample)
GB (1) GB0303609D0 (enExample)
WO (1) WO2004073622A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010520166A (ja) * 2007-02-28 2010-06-10 ジュリアーニ インターナショナル リミテッド 免疫保護性刺激物質としてカチオン性抗菌ペプチド発現を誘導するためのＰＰＡＲ−γアゴニスト

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20050390A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
ITRM20050389A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
FR2894477A1 (fr) * 2005-12-13 2007-06-15 Galderma Res & Dev Utilisation du naveglitazar pour la preparation d'une composition pharmaceutique destinee au traitement des affections dermatologiques
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
UA107562C2 (uk) 2008-12-05 2015-01-26 Спосіб лікування псоріазу
EP2805746B1 (en) 2009-02-16 2020-05-06 Nogra Pharma Limited Alkylamido compounds and uses thereof
WO2011084824A1 (en) * 2009-12-21 2011-07-14 Sarah Bacus Compositions and methods for increasing cellular fat and bleaching skin
US20110150856A1 (en) 2009-12-21 2011-06-23 Sarah Bacus Compositions and methods for treatment of vitiligo
JP6301844B2 (ja) 2012-02-09 2018-03-28 ノグラ ファーマ リミテッド 線維症の処置方法
AU2013248397A1 (en) 2012-04-18 2014-10-02 Nogra Pharma Limited Methods of treating lactose intolerance
AU2014236510A1 (en) 2013-03-14 2015-09-24 Deuterx, Llc Deuterium-enriched 2,4-thiazolidinediones and methods of treatment
US10188639B2 (en) 2014-01-15 2019-01-29 Deuterx, Llc Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
CA3037958C (en) 2017-02-22 2022-06-14 Jeffrey L. Sugarman Glitazones for topical application
SI3921299T1 (sl) 2019-02-08 2025-03-31 Nogra Pharma Limited Postopek izdelave 3-(4'-aminofenil)-2-metoksipropionske kisline in njenih analogov in vmesnih proizvodov
US11767317B1 (en) 2020-06-30 2023-09-26 Poxel Sa Methods of synthesizing enantiopure deuterium-enriched pioglitazone
US11319313B2 (en) 2020-06-30 2022-05-03 Poxel Sa Crystalline forms of deuterium-enriched pioglitazone

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5594015A (en) * 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
WO2002076177A2 (en) * 2001-03-23 2002-10-03 Bethesda Pharmaceuticals, Inc. Design and synthesis of optimized ligands for ppar
US6831102B2 (en) * 2001-12-07 2004-12-14 Bristol-Myers Squibb Company Phenyl naphthol ligands for thyroid hormone receptor
US6747048B2 (en) * 2002-05-08 2004-06-08 Bristol-Myers Squibb Company Pyridine-based thyroid receptor ligands

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010520166A (ja) * 2007-02-28 2010-06-10 ジュリアーニ インターナショナル リミテッド 免疫保護性刺激物質としてカチオン性抗菌ペプチド発現を誘導するためのＰＰＡＲ−γアゴニスト

Also Published As

Publication number Publication date
WO2004073622A2 (en) 2004-09-02
GB0303609D0 (en) 2003-03-19
EP1594959A2 (en) 2005-11-16
EP1594959A4 (en) 2006-05-03
WO2004073622A3 (en) 2005-01-20

Similar Documents

Publication Publication Date Title
JP2006517973A (ja) 新規な治療方法および局所投与用組成物
KR101715631B1 (ko) 피부 관리를 위한 조성물 및 방법
DK1879595T3 (en) Preparations and Methods for the Treatment of Hyperproliferative Epidermal Diseases
JP3921202B2 (ja) 抗刺激性酒さ治療
US6437002B1 (en) Agent for preventing and treating skin diseases
CA3132958A1 (en) Topical compositions and methods for treating inflammatory skin diseases
CA2740200C (en) Methods and compositions for treating dermatological diseases and conditions
US10869822B2 (en) Compositions for treatment of dermatological diseases and conditions and methods of use thereof
JP2020505469A (ja) 治療用アプレミラスト局所組成物
US20060159648A1 (en) Novel therapeutic method and compositions for topical administration
JP5891651B2 (ja) 角層細胞分化正常化用皮膚外用剤
KR101623375B1 (ko) 키토산 및 디카르복실산을 포함하는 주사 질환의 치료용 조성물
JP2007525420A (ja) 新規な治療方法および局所投与用組成物
RU2630978C2 (ru) Фармацевтические составы для лечения заболеваний и состояний кожи, содержащие 7-(1н-имидазол-4-илметил)-5,6,7,8-тетрагидрохинолин
US20070086967A1 (en) Treatment of psoriasis with rosiglitazone
US20060142356A1 (en) Novel therapeutic method and compositions for topical administration
JP2023184678A (ja) 皮膚線維症を処置するための組成物および方法
US20240180988A1 (en) Use of mangosteen fruit shell extract in the preparation of a medicament for treating bedsores
JP2012506851A (ja) 局所脱色素用組成物及びその使用
JPH08109128A (ja) アレルギー性皮膚疾患治療用外用剤
JP2021527634A (ja) Ｄｇａｔ１阻害剤の局所製剤およびそれらの使用の方法
EP3752139A1 (en) Topical capecitabine for the treatment of hyperproliferative skin conditions
Chadha Design, Optimization and Evaluation of a Novel Emulgel of Ibuprofen for Enhanced Skin Delivery using Formulating for Efficacy™ software
KR20080077432A (ko) 히아루론산 및/또는 그것의 염과 ｐｐａｒ 항진제를함유하는 아토피성 피부염의 개선 또는 치료를 위한 조성물
HK1117737B (en) Use of adamantyl methoxydi phenyl propenoic acid for the treatment of acne

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070209

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20100730